Payment overview · 2025
General Payments
$46.90
3 reported records · 2 companies
Healthcare provider profile · identity verified
Charbel Aoun, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VICTORVILLE, CA · NPI 1023121217
Verified facts
What the public records show
CMS Open Payments records show Charbel Aoun, MD received $46.90 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 63.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.53 | 63.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.37 | 37.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.90 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 489 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 97 |
| Metformin Hcl | Metformin Hcl | 280 | 86 |
| Losartan Potassium | Losartan Potassium | 269 | 87 |
| Gabapentin | Gabapentin | 226 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 71 |
| Furosemide | Furosemide | 202 | 70 |
| Lisinopril | Lisinopril | 200 | 62 |
| Ozempic | Semaglutide | 196 | 30 |
| Eliquis | Apixaban | 194 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 57 |
| Potassium Chloride | Potassium Chloride | 155 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 37 |
| Simvastatin | Simvastatin | 122 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 36 |
| Carvedilol | Carvedilol | 118 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 36 |
| Meloxicam | Meloxicam | 112 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 75 |
| Alprazolam | Alprazolam | 106 | 21 |
| Glipizide | Glipizide | 106 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 36 |
| Tramadol Hcl | Tramadol Hcl | 104 | 28 |
| Farxiga | Dapagliflozin Propanediol | 101 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 26 |
| Jardiance | Empagliflozin | 99 | 29 |
| Ezetimibe | Ezetimibe | 95 | 29 |
| Famotidine | Famotidine | 95 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 35 |
| Omeprazole | Omeprazole | 92 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 30 |
| Allopurinol | Allopurinol | 83 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 58 |
| Mounjaro | Tirzepatide | 76 | 18 |
| Finasteride | Finasteride | 75 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 73 | 29 |
| Nifedipine Er | Nifedipine | 71 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 29 |
| Donepezil Hcl | Donepezil Hcl | 68 | 18 |
| Prednisone | Prednisone | 67 | 30 |
| Cephalexin | Cephalexin | 66 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 63 | 17 |
| Temazepam | Temazepam | 60 | 13 |
| Lorazepam | Lorazepam | 59 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 42 |
| Entresto | Sacubitril/Valsartan | 50 | 15 |
| Spironolactone | Spironolactone | 50 | 14 |
| Valsartan | Valsartan | 50 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 12 |
| Kerendia | Finerenone | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Lactulose | Lactulose | 45 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Verquvo | Vericiguat | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | 12 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 23 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 33 | suppressed |
| Sucralfate | Sucralfate | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 12 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 28 |
| Alendronate Sodium | Alendronate Sodium | 30 | 13 |
| Ondansetron Odt | Ondansetron | 30 | 15 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Constulose | Lactulose | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 20 |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Diazepam | Diazepam | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | 15 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 13 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 11 |
| Tradjenta | Linagliptin | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.90 · 3 records | PFIZER INC. | NURTEC ODT, SHINGRIX, VYNDAQEL, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error